Seminars in Liver Disease

Papers
(The median citation count of Seminars in Liver Disease is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Hepatic Stellate Cell–Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis75
The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis60
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity53
Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review40
Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials34
Alagille Syndrome: A Focused Review on Clinical Features, Genetics, and Treatment29
Direct or Collateral Liver Damage in SARS-CoV-2–Infected Patients28
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities27
Interleukin-17 in Liver Disease Pathogenesis27
Hepatic Alveolar Echinococcosis26
Cellular Senescence in Liver Disease and Regeneration26
The Role of Liver Zonation in Physiology, Regeneration, and Disease20
Simplification of Care for Chronic Hepatitis C Virus Infection20
Machine Perfusion: Cold versus Warm, versus Neither. Update on Clinical Trials19
Molecular Mechanisms of Hepatoblastoma19
Management of Acute Liver Failure: Update 202218
Early Diagnosis and Prevention of Infections in Cirrhosis17
Liver Matrix in Benign and Malignant Biliary Tract Disease16
Aging and Chronic Liver Disease16
Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update15
Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives14
Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis14
Plasma Exchange in Acute and Acute on Chronic Liver Failure14
Evolution of Liver Transplant Selection Criteria and U.S. Allocation Policy for Patients with Hepatocellular Carcinoma14
Nonalcoholic Fatty Liver Disease: Current Global Burden14
A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination13
Hepatitis C Virus Treatment in Children: A Challenge for Hepatitis C Virus Elimination13
Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC)—Multi-Omic and Singulomic Approaches12
Role of Multidisciplinary Care in the Management of Hepatocellular Carcinoma12
Wearables, Physical Activity, and Exercise Testing in Liver Disease12
The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone12
Intrahepatic Cholestasis of Pregnancy: Natural History and Current Management12
Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future12
Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review12
Differential Roles for Diploid and Polyploid Hepatocytes in Acute and Chronic Liver Injury12
The Current Status of Granulocyte-Colony Stimulating Factor to Treat Acute-on-Chronic Liver Failure11
Shared Mechanisms between Cardiovascular Disease and NAFLD11
Gut–Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers10
New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease10
Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?10
Risks and Rewards of Bariatric Surgery in Advanced Chronic Liver Diseases9
Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems9
Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review9
Nonalcoholic Steatohepatitis Promoting Kinases9
Scavenger Receptors: Novel Roles in the Pathogenesis of Liver Inflammation and Cancer9
Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD8
Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations8
Organoids for the Study of Liver Cancer8
The Neglected Role of Bile Duct Epithelial Cells in NASH8
Insights into the Role of Granulocyte Colony-Stimulating Factor in Severe Alcoholic Hepatitis8
Drug-Induced Vanishing Bile Duct Syndrome: From Pathogenesis to Diagnosis and Therapeutics8
Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy7
Toward a Liver Cell Atlas: Understanding Liver Biology in Health and Disease at Single-Cell Resolution7
Noninvasive Algorithms for the Case Finding of “At-Risk” Patients with NAFLD7
The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma7
Management of Portal Vein Thrombosis in Cirrhosis7
NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?7
Role of YAP1 Signaling in Biliary Development, Repair, and Disease7
Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective7
Role of Lipogenesis Rewiring in Hepatocellular Carcinoma7
Circadian Regulation of Gene Expression and Metabolism in the Liver6
Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells6
Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma6
MRGPRX4 in Cholestatic Pruritus6
Mesenchymal Stem Cell Transplantation in Liver Diseases5
Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease5
Hepatitis B Core-Related Antigen: From Virology to Clinical Application5
Fontan-Associated Liver Disease: Pathophysiology, Staging, and Management4
The Role of Lymphatics in Cholestasis: A Comprehensive Review4
Novel Mechanisms for Resolution of Liver Inflammation: Therapeutic Implications4
Novel Biomarkers of AKI in Cirrhosis4
To TIPS or Not to TIPS in High Risk of Variceal Rebleeding and Acute-on-Chronic Liver Failure4
Recurrent Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Directions4
Growth Hormone Signaling in Liver Diseases: Therapeutic Potentials and Controversies4
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms4
Therapeutic Pipeline in Alcohol-Associated Liver Disease4
Unraveling the Complexity of Liver Disease One Cell at a Time4
Short Telomeres: Cause and Consequence in Liver Disease4
The Changing Epidemiology of Alcohol-Associated Liver Disease: Gender, Race, and Risk Factors4
Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective3
Hepatocellular Carcinoma Chemoprevention with Generic Agents3
HNF4α in Hepatocyte Health and Disease3
Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids3
Liver Transplantation Selection and Allocation Criteria for Hepatocellular Carcinoma: A European Perspective3
Alcohol Use Disorder and Hepatitis C Prevention and Care in People Who Inject Drugs: The State of Play3
Donation after Circulatory Death: Potential Mechanisms of Injury and Preventative Strategies3
Endoscopic Advances in Hepatology3
0.019569158554077